Skip to content
The Policy VaultThe Policy Vault

Ojjaara (momelotinib tablets)Cigna

Accelerated or Blast Phase Myeloproliferative Neoplasm

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has at least one disease-related symptom (e.g., fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, leukocytosis)

Approval duration

1 year